|
NR3C1 |
nuclear receptor subfamily 3 group C member 1 |
- HSP90 chaperone cycle for steroid hormone receptors (SHR)
- Circadian Clock
- SUMOylation of intracellular receptors
- PTK6 Expression
- Regulation of RUNX2 expression and activity
- FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
- Potential therapeutics for SARS
|
- Flunisolide
- Diflorasone
- Alclometasone
- Medrysone
- Amcinonide
- Fluorometholone
- Megestrol acetate
- Levonorgestrel
- Beclomethasone dipropionate
- Progesterone
- Spironolactone
- Betamethasone
- Desoximetasone
- Fluticasone propionate
- Fluocinolone acetonide
- Ulobetasol
- Triamcinolone
- Prednisone
- Flumethasone
- Fludrocortisone
- Norethisterone
- Hydrocortisone
- Mometasone
- Hydrocortamate
- Mifepristone
- Clocortolone
- Flurandrenolide
- Prednisolone
- Loteprednol etabonate
- Rimexolone
- Methylprednisolone
- Clobetasol propionate
- Fluocinonide
- Prednicarbate
- Fluoxymesterone
- Budesonide
- Dexamethasone
- Desonide
- Cortisone acetate
- Paramethasone
- Drospirenone
- Ciclesonide
- Hexane-1,6-Diol
- Aldosterone
- ORG-34517
- Difluprednate
- Ulipristal
- Fluticasone furoate
- Tixocortol
- Difluocortolone
- Gestrinone
- Deflazacort
- Onapristone
- Cortivazol
- Clobetasone
- Fluticasone
- Mometasone furoate
- Hydrocortisone aceponate
- Hydrocortisone acetate
- Hydrocortisone butyrate
- Hydrocortisone cypionate
- Hydrocortisone phosphate
- Hydrocortisone probutate
- Hydrocortisone valerate
- Segesterone acetate
- Prednisolone phosphate
- Dexamethasone acetate
- Betamethasone phosphate
- Prednisolone acetate
|
- 46,XX disorders of sex development (Disorders related to androgen excess), including: Congenital adrenal hyperplasias; Glucocorticoid resistance; Aromatase deficiency
|
|
PARP1 |
poly(ADP-ribose) polymerase 1 |
- POLB-Dependent Long Patch Base Excision Repair
- vRNA Synthesis
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SUMOylation of DNA damage response and repair proteins
- HDR through MMEJ (alt-NHEJ)
- DNA Damage Recognition in GG-NER
- Formation of Incision Complex in GG-NER
- Dual Incision in GG-NER
|
- Theophylline
- Zinc
- Carba-nicotinamide-adenine-dinucleotide
- NU1025
- Nicotinamide
- 2-{3-[4-(4-Fluorophenyl)-3,6-Dihydro-1(2h)-Pyridinyl]Propyl}-8-Methyl-4(3h)-Quinazolinone
- 3-Methoxybenzamide
- 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide
- 3,4-Dihydro-5-Methyl-Isoquinolinone
- 2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide
- 6-AMINO-BENZO[DE]ISOQUINOLINE-1,3-DIONE
- Veliparib
- A-620223
- 5-FLUORO-1-[4-(4-PHENYL-3,6-DIHYDROPYRIDIN-1(2H)-YL)BUTYL]QUINAZOLINE-2,4(1H,3H)-DIONE
- Olaparib
- Talazoparib
- Niraparib
- Rucaparib
- Iniparib
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
|
|
|
PDCD11 |
programmed cell death 11 |
- rRNA modification in the nucleus and cytosol
- Major pathway of rRNA processing in the nucleolus and cytosol
|
|
|
|
PGR |
progesterone receptor |
- Nuclear signaling by ERBB4
- HSP90 chaperone cycle for steroid hormone receptors (SHR)
- Nuclear Receptor transcription pathway
- SUMOylation of intracellular receptors
- Estrogen-dependent gene expression
|
- Etonogestrel
- Desogestrel
- Megestrol acetate
- Levonorgestrel
- Dydrogesterone
- Progesterone
- Spironolactone
- Lindane
- Fluticasone propionate
- Medroxyprogesterone acetate
- Mitotane
- Norethisterone
- Mometasone
- Ethynodiol diacetate
- Mifepristone
- Norgestimate
- Drospirenone
- Danazol
- Oxybenzone
- Allylestrenol
- Phthalic Acid
- Metribolone
- Tanaproget
- Telapristone acetate
- Asoprisnil
- Norelgestromin
- Gestodene
- Hydroxyprogesterone caproate
- Ulipristal
- Fluticasone furoate
- Dienogest
- Medrogestone
- Norgestrel
- Homosalate
- Enzacamene
- Gestrinone
- Darolutamide
- Demegestone
- Fluticasone
- Mometasone furoate
- Segesterone acetate
|
|
|
PIAS1 |
protein inhibitor of activated STAT 1 |
- SUMOylation of DNA damage response and repair proteins
- SUMOylation of transcription factors
- SUMOylation of ubiquitinylation proteins
- SUMOylation of transcription cofactors
- SUMOylation of intracellular receptors
- SUMOylation of intracellular receptors
- SUMOylation of chromatin organization proteins
- Formation of Incision Complex in GG-NER
- Regulation of IFNG signaling
|
|
|
|
PIAS3 |
protein inhibitor of activated STAT 3 |
- SUMOylation of transcription factors
- SUMOylation of transcription cofactors
- SUMOylation of intracellular receptors
- SUMOylation of DNA replication proteins
- SUMOylation of immune response proteins
- Formation of Incision Complex in GG-NER
|
|
|
|
PIK3CA |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
- PI3K Cascade
- IRS-mediated signalling
- GPVI-mediated activation cascade
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- PI3K events in ERBB4 signaling
- PIP3 activates AKT signaling
- Signaling by SCF-KIT
- Synthesis of PIPs at the plasma membrane
- GAB1 signalosome
- Signaling by cytosolic FGFR1 fusion mutants
- Downstream signal transduction
- PI3K events in ERBB2 signaling
- PI3K/AKT activation
- Downstream TCR signaling
- Role of phospholipids in phagocytosis
- Tie2 Signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- DAP12 signaling
- Role of LAT2/NTAL/LAB on calcium mobilization
- Nephrin family interactions
- Costimulation by the CD28 family
- CD28 dependent PI3K/Akt signaling
- G alpha (q) signalling events
- VEGFA-VEGFR2 Pathway
- VEGFA-VEGFR2 Pathway
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Constitutive Signaling by EGFRvIII
- PI-3K cascade:FGFR1
- PI-3K cascade:FGFR2
- PI-3K cascade:FGFR3
- PI-3K cascade:FGFR4
- Signaling by FGFR2 in disease
- Signaling by FGFR4 in disease
- Signaling by FGFR1 in disease
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- MET activates PI3K/AKT signaling
- Signaling by FGFR3 fusions in cancer
- Signaling by FGFR3 point mutants in cancer
- RET signaling
- Extra-nuclear estrogen signaling
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Activated NTRK2 signals through PI3K
- Interleukin receptor SHC signaling
- Regulation of signaling by CBL
- Regulation of signaling by CBL
- Activated NTRK3 signals through PI3K
- FLT3 Signaling
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
- Signaling by PDGFRA extracellular domain mutants
- Signaling by FLT3 fusion proteins
- Signaling by FLT3 ITD and TKD mutants
|
- ATP
- Caffeine
- XL765
- Wortmannin
- Pilaralisib
- Alpelisib
- Copanlisib
|
|
|
PIN1 |
peptidylprolyl cis/trans isomerase, NIMA-interacting 1 |
- ISG15 antiviral mechanism
- RHO GTPases Activate NADPH Oxidases
- Regulation of TP53 Activity through Phosphorylation
- PI5P Regulates TP53 Acetylation
- Negative regulators of DDX58/IFIH1 signaling
|
- Beta-(2-Naphthyl)-Alanine
- 3,6,9,12,15,18-HEXAOXAICOSANE
|
|
|
PKM |
pyruvate kinase M1/2 |
|
- Pyruvic acid
- L-Phospholactate
- 2-Phosphoglycolic Acid
- 6-(2-fluorobenzyl)-2,4-dimethyl-4,6-dihydro-5H-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one
- 1-[(2,6-difluorophenyl)sulfonyl]-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine
- 1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-[(4-methoxyphenyl)sulfonyl]piperazine
- Copper
- Artenimol
|
|
|
PLA2G4A |
phospholipase A2 group IVA |
- phospho-PLA2 pathway
- Acyl chain remodelling of PC
- Acyl chain remodeling of CL
- Acyl chain remodelling of PS
- Acyl chain remodelling of PE
- Acyl chain remodelling of PI
- Acyl chain remodelling of PG
- Hydrolysis of LPC
- Synthesis of PA
- Arachidonic acid metabolism
- ADP signalling through P2Y purinoceptor 1
- Platelet sensitization by LDL
- COPI-independent Golgi-to-ER retrograde traffic
|
- Fluticasone propionate
- Procaine
- Quinacrine
- Niflumic acid
- Darapladib
- Fluticasone
|
|
|
PLK1 |
polo like kinase 1 |
- Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
- Polo-like kinase mediated events
- Golgi Cisternae Pericentriolar Stack Reorganization
- Golgi Cisternae Pericentriolar Stack Reorganization
- APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
- Phosphorylation of the APC/C
- Phosphorylation of Emi1
- Condensation of Prophase Chromosomes
- Separation of Sister Chromatids
- Resolution of Sister Chromatid Cohesion
- Regulation of PLK1 Activity at G2/M Transition
- Activation of NIMA Kinases NEK9, NEK6, NEK7
- Loss of Nlp from mitotic centrosomes
- Recruitment of mitotic centrosome proteins and complexes
- Loss of proteins required for interphase microtubule organization from the centrosome
- Recruitment of NuMA to mitotic centrosomes
- Anchoring of the basal body to the plasma membrane
- RHO GTPases Activate Formins
- Mitotic Prometaphase
- Mitotic Metaphase/Anaphase Transition
- Mitotic Telophase/Cytokinesis
- Cyclin A/B1/B2 associated events during G2/M transition
- The role of GTSE1 in G2/M progression after G2 checkpoint
- AURKA Activation by TPX2
- EML4 and NUDC in mitotic spindle formation
|
- 3-[3-chloro-5-(5-{[(1S)-1-phenylethyl]amino}isoxazolo[5,4-c]pyridin-3-yl)phenyl]propan-1-ol
- 3-[3-(3-methyl-6-{[(1S)-1-phenylethyl]amino}-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl]propanamide
- 4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE
- 1-[5-Methyl-2-(trifluoromethyl)furan-3-yl]-3-[5-[2-[[6-(1H-1,2,4-triazol-5-ylamino)pyrimidin-4-yl]amino]ethyl]-1,3-thiazol-2-yl]urea
- Wortmannin
- Fostamatinib
|
|
|
PML |
PML nuclear body scaffold |
- SUMOylation of DNA damage response and repair proteins
- SUMOylation of ubiquitinylation proteins
- Regulation of TP53 Activity through Acetylation
- Interferon gamma signaling
- Regulation of RUNX1 Expression and Activity
- Regulation of PTEN localization
- HCMV Early Events
|
|
- Acute myeloid leukemia (AML)
|
|
POU2F1 |
POU class 2 homeobox 1 |
- Interleukin-4 and Interleukin-13 signaling
- RNA polymerase II transcribes snRNA genes
- RNA polymerase II transcribes snRNA genes
- RNA Polymerase III Abortive And Retractive Initiation
- RNA Polymerase III Transcription Initiation From Type 3 Promoter
- RNA Polymerase III Transcription Initiation From Type 3 Promoter
- Estrogen-dependent gene expression
|
|
|
|
POU6F2 |
POU class 6 homeobox 2 |
|
|
|
|
PPARA |
peroxisome proliferator activated receptor alpha |
- RORA activates gene expression
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- PPARA activates gene expression
- PPARA activates gene expression
- Transcriptional activation of mitochondrial biogenesis
- Activation of gene expression by SREBF (SREBP)
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by PPARalpha
- Circadian Clock
- SUMOylation of intracellular receptors
|
- alpha-Linolenic acid
- Icosapent
- Troglitazone
- Valproic acid
- Indomethacin
- Rosiglitazone
- Fenoprofen
- Clofibrate
- Fenofibrate
- Ibuprofen
- Amiodarone
- Gemfibrozil
- Bezafibrate
- Prasterone
- N,N-Bis(3-(D-gluconamido)propyl)deoxycholamide
- Flufenamic acid
- Resveratrol
- Phthalic Acid
- Lauric acid
- Stearic acid
- Doconexent
- Palmitic Acid
- Oleic Acid
- Caprylic acid
- Arachidonic Acid
- Reglitazar
- Elafibranor
- Cardarine
- Muraglitazar
- Ertiprotafib
- Ragaglitazar
- Tesaglitazar
- GW-590735
- Indeglitazar
- Myristic acid
- Aleglitazar
- Clinofibrate
- Ciprofibrate
- Dexibuprofen
- Soybean oil
- Omega-3 fatty acids
- Myrrh
- Isoflavone
- Leukotriene B4
- Fenofibric acid
- Fish oil
|
|
|
PPARG |
peroxisome proliferator activated receptor gamma |
- PPARA activates gene expression
- Transcriptional regulation of white adipocyte differentiation
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- SUMOylation of intracellular receptors
- Regulation of PTEN gene transcription
- Regulation of PTEN gene transcription
- MECP2 regulates transcription factors
|
- alpha-Linolenic acid
- Icosapent
- Troglitazone
- Mesalazine
- Valproic acid
- Indomethacin
- Rosiglitazone
- Fenoprofen
- Nateglinide
- Sulfasalazine
- Clofazimine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Amiodarone
- Pioglitazone
- Mitiglinide
- Bezafibrate
- Flufenamic acid
- Resveratrol
- Phthalic Acid
- Capric acid
- Doconexent
- Oleic Acid
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- Reglitazar
- Elafibranor
- AMG-131
- CLX-0921
- Muraglitazar
- Ertiprotafib
- Ragaglitazar
- Tesaglitazar
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- 9(S)-HODE
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- Indeglitazar
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- Triclosan
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- Aleglitazar
- Clinofibrate
- Cannabidiol
- Lobeglitazone
- Ciglitazone
- Dexibuprofen
- Omega-3 fatty acids
- Curcumin
- Arhalofenate
- Isoflavone
- Naveglitazar
- Fenofibric acid
- Fish oil
- Medical Cannabis
- Nabiximols
- Darglitazone
- Curcumin sulfate
|
- Type II diabetes mellitus
- Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy
- Thyroid cancer
|
|
PPP1R13L |
protein phosphatase 1 regulatory subunit 13 like |
- Regulation of TP53 Activity through Association with Co-factors
|
|
|
|
PPP2CA |
protein phosphatase 2 catalytic subunit alpha |
- Inhibition of replication initiation of damaged DNA by RB1/E2F1
- Spry regulation of FGF signaling
- Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
- Integration of energy metabolism
- PP2A-mediated dephosphorylation of key metabolic factors
- DARPP-32 events
- Degradation of beta-catenin by the destruction complex
- Beta-catenin phosphorylation cascade
- ERK/MAPK targets
- ERKs are inactivated
- MASTL Facilitates Mitotic Progression
- Separation of Sister Chromatids
- Resolution of Sister Chromatid Cohesion
- Initiation of Nuclear Envelope (NE) Reformation
- CTLA4 inhibitory signaling
- Platelet sensitization by LDL
- Disassembly of the destruction complex and recruitment of AXIN to the membrane
- Disassembly of the destruction complex and recruitment of AXIN to the membrane
- Signaling by GSK3beta mutants
- S33 mutants of beta-catenin aren't phosphorylated
- S37 mutants of beta-catenin aren't phosphorylated
- S45 mutants of beta-catenin aren't phosphorylated
- T41 mutants of beta-catenin aren't phosphorylated
- APC truncation mutants have impaired AXIN binding
- AXIN missense mutants destabilize the destruction complex
- Truncations of AMER1 destabilize the destruction complex
- RHO GTPases Activate Formins
- RAF activation
- Negative regulation of MAPK pathway
- Regulation of TP53 Degradation
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Mitotic Prometaphase
- Cyclin D associated events in G1
- Cyclin A/B1/B2 associated events during G2/M transition
- Regulation of glycolysis by fructose 2,6-bisphosphate metabolism
- EML4 and NUDC in mitotic spindle formation
- Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
|
- Vitamin E
- 2,6,8-Trimethyl-3-Amino-9-Benzyl-9-Methoxynonanoic Acid
- (2S,3S,4E,6E,8S,9S)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid
|
|
|
PPP2CB |
protein phosphatase 2 catalytic subunit beta |
- Inhibition of replication initiation of damaged DNA by RB1/E2F1
- Spry regulation of FGF signaling
- Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
- Integration of energy metabolism
- PP2A-mediated dephosphorylation of key metabolic factors
- DARPP-32 events
- Degradation of beta-catenin by the destruction complex
- Beta-catenin phosphorylation cascade
- ERK/MAPK targets
- ERKs are inactivated
- MASTL Facilitates Mitotic Progression
- Separation of Sister Chromatids
- Resolution of Sister Chromatid Cohesion
- CTLA4 inhibitory signaling
- Platelet sensitization by LDL
- Disassembly of the destruction complex and recruitment of AXIN to the membrane
- Disassembly of the destruction complex and recruitment of AXIN to the membrane
- Signaling by GSK3beta mutants
- S33 mutants of beta-catenin aren't phosphorylated
- S37 mutants of beta-catenin aren't phosphorylated
- S45 mutants of beta-catenin aren't phosphorylated
- T41 mutants of beta-catenin aren't phosphorylated
- APC truncation mutants have impaired AXIN binding
- AXIN missense mutants destabilize the destruction complex
- Truncations of AMER1 destabilize the destruction complex
- RHO GTPases Activate Formins
- RAF activation
- Negative regulation of MAPK pathway
- Regulation of TP53 Degradation
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Mitotic Prometaphase
- Cyclin D associated events in G1
- Cyclin A/B1/B2 associated events during G2/M transition
- Regulation of glycolysis by fructose 2,6-bisphosphate metabolism
- EML4 and NUDC in mitotic spindle formation
|
|
|
|
PPP2R1B |
protein phosphatase 2 scaffold subunit Abeta |
- Inhibition of replication initiation of damaged DNA by RB1/E2F1
- Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
- Integration of energy metabolism
- PP2A-mediated dephosphorylation of key metabolic factors
- DARPP-32 events
- Degradation of beta-catenin by the destruction complex
- Beta-catenin phosphorylation cascade
- ERK/MAPK targets
- ERKs are inactivated
- MASTL Facilitates Mitotic Progression
- Separation of Sister Chromatids
- Resolution of Sister Chromatid Cohesion
- CTLA4 inhibitory signaling
- Platelet sensitization by LDL
- Disassembly of the destruction complex and recruitment of AXIN to the membrane
- Disassembly of the destruction complex and recruitment of AXIN to the membrane
- Signaling by GSK3beta mutants
- S33 mutants of beta-catenin aren't phosphorylated
- S37 mutants of beta-catenin aren't phosphorylated
- S45 mutants of beta-catenin aren't phosphorylated
- T41 mutants of beta-catenin aren't phosphorylated
- APC truncation mutants have impaired AXIN binding
- AXIN missense mutants destabilize the destruction complex
- Truncations of AMER1 destabilize the destruction complex
- RHO GTPases Activate Formins
- RAF activation
- Negative regulation of MAPK pathway
- Regulation of TP53 Degradation
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Mitotic Prometaphase
- Cyclin D associated events in G1
- Cyclin A/B1/B2 associated events during G2/M transition
- Regulation of glycolysis by fructose 2,6-bisphosphate metabolism
- EML4 and NUDC in mitotic spindle formation
|
|
|